AOD-9604

Based on the limited available evidence, AOD-9604 has been investigated primarily for musculoskeletal conditions, with one documented study in osteoarthritis.

Osteoarthritis

The most substantive clinical evidence comes from a single animal study examining AOD-9604's potential in joint health. Research published in Annals of Clinical and Laboratory Science (2015) evaluated intra-articular injection of AOD-9604, both alone and in combination with hyaluronic acid, in a rabbit osteoarthritis model. However, specific efficacy outcomes and safety data from this study are not detailed in the available evidence.

Musculoskeletal and Athletic Applications

AOD-9604 has been discussed in the context of peptide therapies for musculoskeletal injuries and athletic performance enhancement. A 2026 review in Sports Medicine examined the safety and efficacy of various peptide therapies, including AOD-9604, though specific clinical findings for this compound are not elaborated in the available evidence.

Similarly, AOD-9604 appears in discussions of therapeutic peptides in orthopedics, suggesting potential applications in this field, but concrete clinical data supporting these uses is not provided in the current evidence base.

Evidence Limitations

Important note: The clinical evidence for AOD-9604 is extremely limited. No completed human clinical trials were identified in major trial databases. The available evidence consists primarily of analytical studies focused on detection methods for sports doping purposes and one preclinical animal study. The lack of robust human clinical trial data means that efficacy, optimal dosing, and comprehensive safety profiles for any clinical indication remain unestablished.

This information is for educational purposes only and should not be considered medical advice. Consult with a healthcare provider for guidance on any medical condition or treatment.